靶向治疗在急性髓系白血病患者管理中的作用。
The role of targeted therapy in the management of patients with AML.
作者信息
Perl Alexander E
机构信息
Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
出版信息
Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829.
Abstract
Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration's approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.
摘要
2017年，急性髓系白血病（AML）的药物治疗终于发生了重大变革。这是由于美国食品药品监督管理局批准了几种新型靶向药物（米哚妥林、恩杂鲁胺和吉妥珠单抗奥唑米星）。再加上最近批准的柔红霉素/阿糖胞苷新型脂质体制剂（CPX-351/Vyxeos），AML各亚组的治疗标准正在迅速改变。本综述将重点关注目前已获批的药物以及正在研发的有前景的新型药物，并将突出靶向治疗中的争议领域。
相似文献
1
The role of targeted therapy in the management of patients with AML.
Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829.
2
The role of targeted therapy in the management of patients with AML.
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):54-65. doi: 10.1182/asheducation-2017.1.54.
3
Novel Agents for Acute Myeloid Leukemia.
Cancers (Basel). 2018 Nov 9;10(11):429. doi: 10.3390/cancers10110429.
4
The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24.
5
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Onco Targets Ther. 2018 Jun 12;11:3425-3434. doi: 10.2147/OTT.S141212. eCollection 2018.
6
Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Leuk Lymphoma. 2019 Jun;60(6):1354-1369. doi: 10.1080/10428194.2018.1546854. Epub 2019 Jan 17.
7
[Incorporation of novel agents into the treatment for acute myeloid leukemia].
Rinsho Ketsueki. 2018;59(10):1988-1996. doi: 10.11406/rinketsu.59.1988.
8
New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Pharmacotherapy. 2018 Nov;38(11):1143-1154. doi: 10.1002/phar.2180. Epub 2018 Oct 17.
9
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Leuk Res. 2018 Oct;73:58-66. doi: 10.1016/j.leukres.2018.09.001. Epub 2018 Sep 8.
10
Incorporating newer agents in the treatment of acute myeloid leukemia.
Leuk Res. 2018 Nov;74:113-120. doi: 10.1016/j.leukres.2018.10.008. Epub 2018 Oct 19.
引用本文的文献
1
CAR-T cell therapy for cancer: current challenges and future directions.
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
2
A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.
Blood Neoplasia. 2025 Jan 23;2(2):100071. doi: 10.1016/j.bneo.2025.100071. eCollection 2025 May.
3
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.
Ther Adv Hematol. 2024 Sep 14;15:20406207241275376. doi: 10.1177/20406207241275376. eCollection 2024.
4
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia.
Nat Commun. 2024 Jul 2;15(1):5570. doi: 10.1038/s41467-024-49784-y.
5
Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway.
Cell Death Discov. 2024 Jan 18;10(1):35. doi: 10.1038/s41420-024-01800-2.
6
Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome) in Acute Myeloid Leukemia Patients: A 28-Year Institutional Experience.
Acta Haematol. 2024;147(4):457-464. doi: 10.1159/000535399. Epub 2023 Nov 21.
7
Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.
J Exp Clin Cancer Res. 2023 Aug 31;42(1):223. doi: 10.1186/s13046-023-02793-z.
8
Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.
Front Oncol. 2023 Aug 3;13:1204895. doi: 10.3389/fonc.2023.1204895. eCollection 2023.
9
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles.
Commun Med (Lond). 2023 May 17;3(1):68. doi: 10.1038/s43856-023-00298-6.
10
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.
Cancers (Basel). 2023 Feb 7;15(4):1044. doi: 10.3390/cancers15041044.
本文引用的文献
1
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
JAMA Oncol. 2018 Aug 1;4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695.
2
Targeting BCL-2-like Proteins to Kill Cancer Cells.
Trends Cancer. 2016 Aug;2(8):443-460. doi: 10.1016/j.trecan.2016.07.001. Epub 2016 Jul 30.
3
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
4
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
5
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
6
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.
7
Midostaurin approved for FLT3-mutated AML.
Blood. 2017 Jun 29;129(26):3403-3406. doi: 10.1182/blood-2017-05-782292. Epub 2017 May 25.
8
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Mutations.
Cancer Discov. 2017 May;7(5):478-493. doi: 10.1158/2159-8290.CD-16-1034. Epub 2017 Feb 13.
9
Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.
Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.
10
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
Zotero 插件